Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC0143-0406 vs Insulin Aspart in Type 1 Diabetes
NCT02938572Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2016
- Primary completion
- Jun 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of NNC0143-0406 in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Ratio of suppression of endogenous glucose production relative to total glucose lowering effect at 2 weeks. Started Oct 2016; status: completed.
02
Drugs
NNC0143-0406
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT02938572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02938572.